Epigenomics AG (Epigenomics AG) Net Income From Continuing Operations : $-17.28 Mil (TTM As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Epigenomics AG Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Epigenomics AG's net income from continuing operations for the three months ended in Jun. 2023 was $-2.85 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2023 was $-17.28 Mil.

Epigenomics AG Net Income From Continuing Operations Historical Data

The historical data trend for Epigenomics AG's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG Net Income From Continuing Operations Chart

Epigenomics AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Income From Continuing Operations

Get a 7-Day Free Trial

-14.44

-18.91

-14.22

-2.74

-12.74

Epigenomics AG Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Net Income From Continuing Operations	Get a 7-Day Free Trial															-1.37	-1.55	-6.89	-5.99	-2.85

Epigenomics AG Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.28 Mil.

Epigenomics AG (Epigenomics AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (OTCPK:EPGNF) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

ECX:Germany

Address

Geneststrasse 5, Berlin, BB, DEU, 10829

Website

https://www.epigenomics.com

Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

Epigenomics AG (Epigenomics AG) Headlines

From GuruFocus

Encode Ideas, L.P. to host Virtual 1x1 Webinar with Epigenomics AG (ECX.DE, EPGNF) on Tuesday, July 28th at 10:30 AM ET

By ACCESSWIRE ACCESSWIRE • 07-23-2020